New York Genome Center

Vertex Appoints Nancy Thornberry to its Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Genetics, Health, Biometrics, New York Genome Center, Chemistry, Senior, Therapy, Sickle cell disease, Biology, GV (company), Patient, Obesity, VRTX, Diabetes, DPP-4, Muhlenberg College, Merck & Co., Cystic fibrosis, Vertex Pharmaceuticals, Pharmaceutical industry, Endocrinology, Science, Vertex, Merck

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.
  • She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development.
  • “Scientific innovation is a core Vertex value and Nancy brings to our Board deep scientific expertise and a remarkable track record of discovering and developing groundbreaking medicines.
  • And today, they are on the cusp of transforming the treatment of multiple additional serious diseases,” said Nancy Thornberry.

Study Details Immune Cells Vital to Success of Vaccines against Coronavirus

Retrieved on: 
Thursday, September 21, 2023
Vaccine, CD38, Antigen, CT, Vaccination, SARS-CoV-2, Neoplasm, HHMI, Coronavirus, Infection, COVID-19, NYU, G1, New York University Grossman School of Medicine, Howard Hughes Medical Institute, Breast, Research, Gene expression, Department of Medicine – University of Pamplona, Cell, RNA, Immunotherapy, Doctor of Philosophy, National Institutes of Health, Messenger, Lung, Bangladesh Technical Education Board, Upadhyay, NYU Langone Health, BioNTech, Chan Zuckerberg Initiative, Protein, KLRG1, CD8, Cell biology, Patient, HCA, Blood, New York Genome Center, Immune system, Faculty, Bacteria, Oncology, Littman, Immunization, Helen, Virus, Prostate cancer, MD, Nature Immunology, Pfizer

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- A study has revealed new details about a key population of immune system cells critical to successful vaccination against the pandemic virus, SARS-CoV-2.

Key Points: 
  • A subset of T cells, labeled with the surface protein CD8, produce molecules that directly kill infected cells.
  • B cells produce antibody proteins that neutralize and label infected cells for removal from the body.
  • The mRNA vaccines deployed against COVID-19 were based on RNA, a genetic material used to encode the spike protein that the virus needs to attach to human cells.
  • "Although our study looks at mRNA vaccination against coronavirus, the antigen-specific CD8+ T cell subpopulations we uncover represent key features of immune responses more broadly, and may help us to study T cells in other disease settings."

BD² ANNOUNCES $18 MILLION IN GRANTS TO UNDERSTAND BIOLOGY OF BIPOLAR DISORDER

Retrieved on: 
Tuesday, September 19, 2023
Yale University, Science, Therapy, Stanford University, Harvard University, Coalition, Sleep, Research, ASAP, Mount Sinai, Bangladesh Technical Education Board, Doctor of Philosophy, Bipolar disorder, Nebraska Religious Coalition for Science Education, Discovery, Parkinson's disease, Wyss Institute, Icahn School of Medicine at Mount Sinai, Milken Institute, Biology, Wyss Institute for Biologically Inspired Engineering, Gene, Chair, Research fellow, Management, Pharmaceutical industry, Lithium, New York Genome Center, MD, Medicine

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its first round of Discovery Research grants, totaling $18 million, bringing greater collaboration and focused funding to the field of bipolar disorder. Multidisciplinary teams of scientists and clinicians, whose leads are at Yale University, Stanford University, New York Genome Center, and the Wyss Institute at Harvard University, will each receive grants of up to $4.5 million over three years to examine the fundamental mechanisms of bipolar disorder. Building on the success and enthusiasm from the field, BD² also announced the second round of funding for the program, inviting interested research teams to apply for grants of the same amount.

Key Points: 
  • "These teams of scientists will work within their own institutions and collaborate across teams to explore hypotheses on the biological causes of bipolar disorder."
  • These studies will expand knowledge about bipolar disorder biology and may translate that into pharmacological therapeutics and behavioral interventions.
  • BD² invites scientists across disciplines to learn more about and apply for this funding opportunity for bipolar disorder research.
  • In its first year, BD² has already dedicated more than $60 million in funding to research that accelerates scientific understanding of bipolar disorder and advances clinical care through cross-disciplinary collaboration, data sharing, and real-time learning.

bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist

Retrieved on: 
Thursday, May 11, 2023
Professional Services, Health, Genetics, Finance, General Health, Research, Science, Transfer, Columbia University, Drug development, University, Professional Football Compensation Committee, Rockefeller University, Audit, Cancer, Multimedia, Medicine, Cell, Technical Guidelines Development Committee, Regenerative medicine, Patient, Brown University, New York Genome Center, Chartered Financial Analyst, Rockefeller, Drug discovery, Hospital, B cell, Laboratory, Fine chemical, Pharmaceutical industry

Cell coding company bit.bio today announces the addition of its early stage investor Weslie Janeway as a Board member.

Key Points: 
  • Cell coding company bit.bio today announces the addition of its early stage investor Weslie Janeway as a Board member.
  • This will pave the way for medicine personalisation from the start of the medicine development process.
  • I’m now looking forward to supporting the company as a board member using my scientific background as well.
  • She brings over 20 years experience as an investor, philanthropist, scientist and author to the company.

BD² Announces First $15 Million in Grants to Advance Genetic and Biological Understanding of Bipolar Disorder

Retrieved on: 
Thursday, March 30, 2023
California Institute of Technology, University of Pittsburgh, Broad Institute, University, Population genetics, Life, Icahn School of Medicine at Mount Sinai, Genetics, MT, California Institute for Telecommunications and Information Technology, Analytic, Research, Mount Sinai, MIT, Cell, Doctor of Philosophy, Harvard University, Organization, Bipolar disorder, DSM-IV codes, Child, New York Genome Center, Diagnosis, Hospital, UCLA, Massachusetts General Hospital, Gene, Bipolar, Pharmaceutical industry, Lithium, Vaccine, Management, MD, Medicine

WASHINGTON, March 30, 2023 /PRNewswire/ -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its first grants, totaling $15 million, to advance scientific understanding of the genetic and biological foundations of bipolar disorder. These first-of-their-kind efforts aim to accelerate discovery and improve diagnosis and care for the more than 40 million people with bipolar disorder.

Key Points: 
  • These first-of-their-kind efforts aim to accelerate discovery and improve diagnosis and care for the more than 40 million people with bipolar disorder.
  • "These grants aim to close a fundamental gap in understanding of bipolar disorder," said Kent Dauten, a founding board member of BD² and longtime funder of bipolar disorder genetics research.
  • "This foundational research is one step toward the many breakthroughs that will help all people with bipolar disorder thrive."
  • Bipolar disorder is highly heritable, meaning a parent can pass it on to their child, but it is unclear how and what genes contribute to bipolar.

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Retrieved on: 
Friday, February 24, 2023
Periodic breathing, Splenic infarction, Vital capacity, Glycogen storage disease type II, Safety, Patient, Coordinated Specialty Care, COMET, Cancer, IOPD, Hives, Alglucosidase alfa, Aes, New York Genome Center, Medical genetics, Walking, FVC, Duke University Hospital, YT, Glycogen, Erythema, Pharmaceutical industry, Nursing, Surveying, Pediatrics, Avalglucosidase alfa

Additionally, a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.

Key Points: 
  • Additionally, a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.
  • It is also approved for infantile-onset Pompe disease (IOPD) in certain markets outside of the US.
  • No new safety signals were observed in patients who switched from alglucosidase alfa to Nexviazyme during the extension period.
  • Subgroup analyses were also performed to assess respiratory function outcomes for the 44 patients who switched to Nexviazyme in the long-term extension period of the Phase 3 COMET study.

The New York Genome Center Launches the MacMillan Center for the Study of the Non-Coding Cancer Genome

Retrieved on: 
Thursday, January 19, 2023
Genome, Cell, Element, Metastasis, FRSC, Biomedical Research, DNA, Computational biology, Precision medicine, Breast, Mathematics, Ovary, Transcriptome, Lung, Causality, MacMillan Center for International and Area Studies, Drug resistance, Education, Hematological Cancer Research Investment and Education Act, Proteome, Columbia University, Weill Cornell Medicine, Diagnosis, New York Genome Center, Genomics, Engineering, RNA, Biology, Research, Cancer, Epigenome, Morehouse School of Medicine, Cold Spring Harbor Laboratory, Royal College of Pathologists, Pancreas, Behavior, Memorial Sloan Kettering Cancer Center, Doctor of Philosophy, Northwell Health, Pharmaceutical industry, Management, Vaccine, Oncogenomics, New York University

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- The New York Genome Center (NYGC) announced the launch of the MacMillan Center for the Study of the Non-Coding Cancer Genome (MCSNCG) today, a major new initiative in cancer research to study the role and function of the non-coding genome and epigenome in the evolution, progression, and treatment of multiple cancer types, including breast, ovary, pancreas, gastrointestinal, lung, and hematologic cancers.

Key Points: 
  • The non-coding "dark" genome constitutes 98% of the human genome and it plays an essential regulatory role across all molecular layers of biological complexity (i.e.
  • genome, epigenome, transcriptome, proteome), influencing DNA organization and structure, genome accessibility to regulatory proteins and RNA, and intracellular organelle organization.
  • Therefore, foundational questions regarding the role of the non-coding genome in the development and progression of many cancer types remain unanswered.
  • Samuel Aparicio, FRCPath PhD, FRSC, NYGC's Senior Scientific Director of Cancer Genomics, says, "Decoding causality is fundamental to providing interpretable quantitative explanations of elements of the non-coding genome in cancer.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Technology, Other Health, Health, General Health, Other Science, Research, Infectious Diseases, Nanotechnology, Genetics, Science, Infection, Severe acute respiratory syndrome coronavirus 2, Transdermal, UCPH Department of Biology, Editorial board, University of Washington Department of Bioengineering, Hepatitis B, NIH, United States Air Force Scientific Advisory Board, CRISPR, Associate, ERC, University, CRS, Internal medicine, Stanford University, Engineer, Degenerative disease, Chair, Pharmaceutics, RNA, Molecular Pharmaceutics, New York Genome Center, Scientist, Ludwig Maximilian University of Munich, Doctor of Philosophy, SNF, MIT, Nervous system, Physiology, BS, Y combinator, Computational linguistics, SAB, MS, PRDS, Drug resistance, JCR, Drug delivery, MIT Department of Brain and Cognitive Sciences, Cognitive science, Medical device, Pharmaceutical industry, Brain, Biology, Carver, List of life sciences, Neuroscience, New York University

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.

Nominations Open for the Merkin Prize in Biomedical Technology

Retrieved on: 
Tuesday, November 29, 2022
Weill Cornell Medicine, Broad Institute, Science, Diagnosis, HPN, Student, Life, Patient, Government, Harvard University, Nobel Prize, MIT, Health, Faculty, Cancer, Nobel Prize in Physiology or Medicine, Therapy, Harold E. Varmus, Invention, Medicine, New York Genome Center, Eli, Biomedical technology, Medical device, Pharmaceutical industry, Physiology, MD

CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology , which recognizes novel technologies that have improved human health.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology , which recognizes novel technologies that have improved human health.
  • The winning technology must have made a demonstrable real-world impact on human health by improving the treatment, diagnosis, or prevention of disease.
  • The Merkin Prize is administered by the Broad Institute of MIT and Harvard, one of the world's leading biomedical research institutes.
  • "The Merkin Prize will highlight the inventors of an important medical technology and will demonstrate how their work is transforming healthcare," said Harold Varmus, chair of the selection committee.

Chris Duignan Joins Flourish Research as Chief Financial Officer

Retrieved on: 
Tuesday, November 8, 2022
VP, United States Marine Corps Reserve, Industry, Duignan, NEW, Fairfield University, Naval and Marine Corps Reserve Center, Architecture, PricewaterhouseCoopers, New York Genome Center, CNS, DNA, Accounting, Vaccine, Clinical trial, Research, Diversified Pharmaceutical Services, Financial management, Management, Pharmaceutical industry, Science

NEW YORK,  Nov. 8, 2022 /PRNewswire-PRWeb/ -- Chris Duignan has been named Chief Financial Officer of Flourish Research, a diversified clinical trial company designed to acquire, operate, and integrate large, best-in-class clinical research sites with expertise in studies spanning Phases I-IV.

Key Points: 
  • Chris Duignan, who has been named Chief Financial Officer of Flourish Research, will build the financial infrastructure, lead financial operations, and integrate the acquisitions of the rapidly growing organization.
  • NEW YORK, Nov.8, 2022 /PRNewswire-PRWeb/ -- Chris Duignan has been named Chief Financial Officer of Flourish Research, a diversified clinical trial company designed to acquire, operate, and integrate large, best-in-class clinical research sites with expertise in studies spanning Phases I-IV.
  • Mr. Duignan will build the financial infrastructure, lead financial operations, and integrate the acquisitions of the rapidly growing organization.
  • "Chris brings with him a deep understanding of our industry and the ability to leverage financial management and reporting to help research sites thrive," said Reinhold Schulz, Chief Executive Officer of Flourish.